In vitro activity: Meloxicam significantly reduces HCA-7 and Moser-S colony size. Meloxicam significantly inhibits HCA-7 colony and tumor growth but has no effect on the growth of the COX-2 negative HCT-116 cells. Meloxicam inhibits PGE(2) production, proliferation and invasiveness especially in MG-63 cells, which express relatively high levels of COX-2. Meloxicam causes apoptosis and upregulates Bax mRNA and protein in MG-63 cell culture.

Cell Assay: CF41.Mg and MDCK cells are seeded at a density of 1.5 × 103 cells/well into 96-well plates, cultured for 24 h and then exposed to 0-25 μg/mL Meloxicam alone or in combination with doxorubicin. To evaluate synergism and sensitization, doxorubicin is added at the same time and after 24 h, respectively. MDCK cells are exposed only to Meloxicam as a non-tumor negative control. Control groups are cultured without Meloxicam and doxorubicin, but the corresponding amount of DMSO is added to the medium. Following an incubation period of 24 and 48 h, cell growth is measured using the MTS assay, with the absorbance at 490 nm determined using a microplate reader. Each experiment is performed 3 times in triplicate.

Carcinogenesis. 1998 Dec;19(12):2195-9; Equine Vet J. 2009 Sep;41(7):693-9; Carcinogenesis. 2006 Mar;27(3):584-92; Am J Vet Res. 2007 Jun;68(6):614-24.